Download by
Scanning QR Code
No Stock Yet
*ST Kehua (002022.SZ) accrued asset impairment reserves in 2022 totaled $316 million
According to the Zhitong Finance App, *ST Kehua (002022.SZ) announced that the total amount of asset impairment provisions calculated by the company in 2022 is 316 million yuan. After considering the impact of income tax and minority shareholders' profit and loss, the company's net profit attributable to shareholders of listed companies in 2022 will be reduced by 197 million yuan, and the company's equity attributable to owners of listed companies at the end of 2022 will be reduced by 197 million yuan.
*ST Kehua (002022.SZ): Application to withdraw the delisting risk warning and other risk warnings
Gelonghui, March 22丨*ST Kehua (002022.SZ) announced that the company held the 29th meeting of the 8th board of directors on March 21, 2023 to review and pass the “Proposal on Application to Revoke the Delisting Risk Warning and Other Risk Warnings of the Company's Stock Trading”. The company has submitted an application to the Shenzhen Stock Exchange for the cancellation of the delisting risk warning and other risk warnings for the company's stock trading.
*ST Kehua (002022.SZ): It is proposed to use no more than 1.8 billion yuan of temporarily idle own funds for cash management
Gelonghui, March 22丨*ST Kehua (002022.SZ) announced that on March 21, 2023, the company held the 29th meeting of the 8th board of directors and the 20th meeting of the 8th board of supervisors to deliberate and pass the “Proposal on the Use of Own Funds by the Company and Subsidiaries for Cash Management”, agreeing that the company and its wholly-owned and holding subsidiaries (all subsidiaries within the scope of consolidated statements, hereinafter collectively referred to as “subsidiaries”) will use a total of no more than RMB 1.8 billion of its own funds for cash management and investment in safety without affecting the company's own normal operations High performance, good fluidity, product
It is proposed to distribute 6 yuan per 10, *ST Kehua (002022.SZ)'s net profit for 2022 will increase 14.16% to 971 million yuan
Gelonghui, March 22丨*ST Kehua (002022.SZ) released its 2022 annual report, achieving operating income of 6.970 billion yuan, an increase of 43.58% over the previous year; net profit attributable to shareholders of listed companies of 971 million yuan, an increase of 14.16% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 952 million yuan, an increase of 13.88% over the previous year; basic earnings per share were 1.8878 yuan, with a proposed cash dividend of 6 yuan (tax included) for every 10 shares. Net cash flow from operating activities was $2.154 billion, an increase of 99.55% over the previous year.
*ST Kehua (002022.SZ): The human immunodeficiency virus antigen antibody (HIVag/Ab) test kit (chemiluminescence) obtained a medical device registration certificate
According to the Zhitong Finance App, *ST Kehua (002022.SZ) issued an announcement. Recently, the company received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the China Drug Administration for the “Human Immunodeficiency Virus Antigen Antibody (HIVAg/Ab) Test Kit (chemiluminescence method)”. It is reported that this product is used to qualitatively test human immunodeficiency virus (HIV1/2) antibodies and HIV-1p24 antigens in human serum or plasma in vitro.
*ST Kehua (002022.SZ) obtained the “Human Immunodeficiency Virus Antigen Antibody Quality Control Product” medical device registration certificate
According to the Zhitong Finance App, *ST Kehua (002022.SZ) issued an announcement. Recently, the company received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the China Drug Administration. The product is: “Human Immunodeficiency Virus Antigen Antibody Quality Control Product”, which complements the company's human immunodeficiency virus antigen antibody (HIVag/Ab) test kit (chemiluminescence) for the quality control of the human immunodeficiency virus antigen antibody test project.
*ST Kehua (002022.SZ) obtained a medical device registration certificate for the hepatitis E virus IgG antibody test kit (ELISA)
According to the Zhitong Finance App, *ST Kehua (002022.SZ) issued an announcement. Recently, the company received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the China Drug Administration. The product is: “Hepatitis E Virus IgG Antibody Test Kit (ELV)”. The product is used to qualitatively test hepatitis E virus IgG antibodies in human serum or plasma samples in vitro.
*ST Kehua: The company's products obtained a medical device registration certificate
Gelonghui announced on March 10丨*ST Kehua announced that the company's product, the hepatitis E virus IgG antibody test kit (ELISA), obtained a medical device registration certificate.
*ST Kehua (002022.SZ): The subsidiary plans to invest 113 million yuan in intelligent medical equipment R&D and production projects
Gelonghui, Feb. 14丨*ST Kehua (002022.SZ) announced that the company held the 28th meeting of the 8th board of directors on February 13, 2023 to review and pass the “Proposal on Additional Investment in the Holding Subsidiary's “Intelligent Medical Device R&D and Production Project”. Xi'an Tianlong Technology Co., Ltd., a holding subsidiary of the company, plans to use its own capital to add about 113 million yuan to the “Smart Medical Device R&D and Production Project”. The total investment of the project will be adjusted from 220 million yuan to about 333 million yuan.
*ST Kehua (002022.SZ) received a medical device registration certificate
According to the Zhitong Finance App, *ST Kehua (002022.SZ) announced that the company has received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the Shanghai Drug Administration. The relevant product is a creatinine test kit (sarcosine oxidase method).
Loading...
No Stock Yet